Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00545688
Registration number
NCT00545688
Ethics application status
Date submitted
16/10/2007
Date registered
17/10/2007
Date last updated
15/08/2017
Titles & IDs
Public title
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Query!
Scientific title
A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer
Query!
Secondary ID [1]
0
0
WO20697
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Herceptin
Treatment: Drugs - Docetaxel
Treatment: Drugs - Pertuzumab
Experimental: 1 -
Experimental: 2 -
Experimental: 3 -
Experimental: 4 -
Treatment: Drugs: Herceptin
8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
Treatment: Drugs: Docetaxel
75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
Treatment: Drugs: Pertuzumab
840mg iv loading dose, followed by 420mg iv 3-weekly
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Pathological Complete Response (pCR)
Query!
Assessment method [1]
0
0
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders
Query!
Timepoint [1]
0
0
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Query!
Primary outcome [2]
0
0
Percentage of Participants Achieving pCR by Breast Cancer Type
Query!
Assessment method [2]
0
0
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.
Query!
Timepoint [2]
0
0
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Query!
Primary outcome [3]
0
0
Percentage of Participants Achieving pCR by Hormone Receptor Status
Query!
Assessment method [3]
0
0
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.
Query!
Timepoint [3]
0
0
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Query!
Primary outcome [4]
0
0
Percentage of Participants Achieving pCR by Lymph Node Status
Query!
Assessment method [4]
0
0
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.
Query!
Timepoint [4]
0
0
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Query!
Primary outcome [5]
0
0
Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)
Query!
Assessment method [5]
0
0
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.
Query!
Timepoint [5]
0
0
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography
Query!
Assessment method [1]
0
0
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.
Query!
Timepoint [1]
0
0
Baseline up to Cycle 4 (assessed at, Baseline and Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography
Query!
Assessment method [2]
0
0
Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Query!
Timepoint [2]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination
Query!
Assessment method [3]
0
0
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Query!
Timepoint [3]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination
Query!
Assessment method [4]
0
0
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Query!
Timepoint [4]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography
Query!
Assessment method [5]
0
0
Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Query!
Timepoint [5]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination
Query!
Assessment method [6]
0
0
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Query!
Timepoint [6]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [7]
0
0
Time to Clinical Response During Neo-Adjuvant Treatment Period
Query!
Assessment method [7]
0
0
Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is >0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.
Query!
Timepoint [7]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period
Query!
Assessment method [8]
0
0
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.
Query!
Timepoint [8]
0
0
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned
Query!
Assessment method [9]
0
0
Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.
Query!
Timepoint [9]
0
0
Surgery (Within 2 weeks after Cycle 4) Up to approximately 24 months
Query!
Secondary outcome [10]
0
0
Percentage of Participants Who Were Progression Free and Disease Free
Query!
Assessment method [10]
0
0
Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.
Query!
Timepoint [10]
0
0
Randomization up to a maximum of 329 weeks
Query!
Secondary outcome [11]
0
0
Progression Free and Disease Free Survival
Query!
Assessment method [11]
0
0
DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.
Query!
Timepoint [11]
0
0
Randomization up to a maximum of 329 weeks
Query!
Eligibility
Key inclusion criteria
- female patients, >=18 years of age;
- locally advanced, inflammatory or early stage invasive breast cancer;
- HER2 positive (HER2+++ by IHC or FISH/CISH+).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- metastatic disease (Stage IV) or bilateral breast cancer;
- previous anticancer therapy or radiotherapy for any malignancy;
- other malignancy, other than cancer in situ of the cervix, or basal cell cancer;
- insulin-dependent diabetes;
- clinically relevant cardiovascular disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/06/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/09/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
417
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Geelong Hospital; Andrew Love Cancer Centre - Geelong
Query!
Recruitment hospital [2]
0
0
Mount Medical Center - Perth
Query!
Recruitment postcode(s) [1]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [2]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Vienna
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Wien
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
RS
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
SC
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
SP
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
New Brunswick
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Ontario
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Quebec
Query!
Country [9]
0
0
Israel
Query!
State/province [9]
0
0
Jerusalem
Query!
Country [10]
0
0
Israel
Query!
State/province [10]
0
0
Kfar-Saba
Query!
Country [11]
0
0
Israel
Query!
State/province [11]
0
0
Tel Aviv
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Emilia-Romagna
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Friuli-Venezia Giulia
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Lombardia
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Veneto
Query!
Country [16]
0
0
Korea, Republic of
Query!
State/province [16]
0
0
Seoul
Query!
Country [17]
0
0
Mexico
Query!
State/province [17]
0
0
Aguascalientes
Query!
Country [18]
0
0
Mexico
Query!
State/province [18]
0
0
Mexico City
Query!
Country [19]
0
0
Mexico
Query!
State/province [19]
0
0
Puebla
Query!
Country [20]
0
0
Peru
Query!
State/province [20]
0
0
Arequipa
Query!
Country [21]
0
0
Peru
Query!
State/province [21]
0
0
Lima
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Lublin
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Olsztyn
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Poznan
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Warszawa
Query!
Country [26]
0
0
Russian Federation
Query!
State/province [26]
0
0
Leningrad
Query!
Country [27]
0
0
Russian Federation
Query!
State/province [27]
0
0
Kazan
Query!
Country [28]
0
0
Russian Federation
Query!
State/province [28]
0
0
Moscow
Query!
Country [29]
0
0
Russian Federation
Query!
State/province [29]
0
0
Petrozavodsk
Query!
Country [30]
0
0
Russian Federation
Query!
State/province [30]
0
0
Pyatigorsk
Query!
Country [31]
0
0
Russian Federation
Query!
State/province [31]
0
0
Ryazan
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Samara
Query!
Country [33]
0
0
Russian Federation
Query!
State/province [33]
0
0
Soshi
Query!
Country [34]
0
0
Russian Federation
Query!
State/province [34]
0
0
St Petersburg
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Ulyanovsk
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Barcelona
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Vizcaya
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Cordoba
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Madrid
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Valencia
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Zaragoza
Query!
Country [42]
0
0
Sweden
Query!
State/province [42]
0
0
Stockholm
Query!
Country [43]
0
0
Sweden
Query!
State/province [43]
0
0
Uppsala
Query!
Country [44]
0
0
Switzerland
Query!
State/province [44]
0
0
Baden
Query!
Country [45]
0
0
Switzerland
Query!
State/province [45]
0
0
Zürich
Query!
Country [46]
0
0
Taiwan
Query!
State/province [46]
0
0
Taipei
Query!
Country [47]
0
0
Thailand
Query!
State/province [47]
0
0
Bangkok
Query!
Country [48]
0
0
Thailand
Query!
State/province [48]
0
0
Songkhla
Query!
Country [49]
0
0
Turkey
Query!
State/province [49]
0
0
Izmir
Query!
Country [50]
0
0
Turkey
Query!
State/province [50]
0
0
Sihhiye, ANKARA
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Coventry
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in
female patients with locally advanced, inflammatory or early stage HER2 positive breast
cancer. Before surgery, patients will be randomized to one of 4 treatment arms, to receive 4
cycles of a)Herceptin + docetaxel b)Herceptin + docetaxel + pertuzumab c)Herceptin +
pertuzumab or 4)pertuzumab + docetaxel. Pertuzumab will be administered at a loading dose of
840mg iv, then 420mg iv 3-weekly, Herceptin at a loading dose of 8mg/kg iv then 6mg/kg
3-weekly, and docetaxel at a dose of 75mg/m2 escalating to 100mg/m2 3-weekly. During the
entire pre- and post-surgery period all patients will receive adequate chemotherapy as per
standard of care, as well as any surgery and/or radiotherapy as required. The anticipated
time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00545688
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00545688
Download to PDF